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Abstract
Background: Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic
therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, and
their levels may be associated with response to immunotherapy. Here, we assess changes in circulating VEGF, as
well as angiogenic cytokines angiopoietin-1 and -2 (Ang1, Ang2), and placental growth factor (PLGF) that occur
during definitive chemo-radiotherapy in HNSCC patients.
Methods: We prospectively collected blood samples from patients receiving definitive radiation with or without
chemotherapy. Serum Ang1, Ang2, VEGF, and PLGF were measured via cytokine assays.
Results: The majority of patients had advanced stage, node positive HPV-associated oropharyngeal cancer, and
received radiation to a median dose of 70 Gy with concurrent cisplatin. Over the course of treatment, serum VEGF
and Ang1 levels decreased in 20/24 (84 %, p < 0.0001) and 21/24 (88 %, p < 0.0001) patients, respectively, and Ang2
and PLGF levels increased in 20/24 (83 %, p < 0.0001) patients.
Conclusions: We find significant changes in angiogenic cytokines in the majority of HNSCC patients over the course of
chemoradiation. Decreases in VEGF caused by radiation may represent one mechanism of potential synergy with
immunotherapy. Increases in Ang2 and PLGF are interesting given their link to tumor associated angiogenesis and poor
prognosis. Additional studies are needed to explore synergies between anti-angiogenic treatments, immunotherapy, and
chemoradiation in HNSCC.
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Background
Head and neck squamous cell carcinoma (HNSCC) affects
greater than 500,000 people across the world annually,
and ranks 6th in global cancer incidence [1]. Tobacco and
alcohol use are the predominant risk factors for tumor de-
velopment worldwide, but the oncogenic human papil-
loma virus (HPV) 16, has also been implicated in disease
pathogenesis, particularly in developed countries [2].
Multimodality treatment, including a combination of
surgery, chemotherapy, and radiation therapy (RT) is
individualized for patients with head and neck cancers,
with many patients receiving radiation either with or with-
out chemotherapy as definitive treatment [3]. Despite re-
cent treatment advances with more refined surgical
techniques such as transoral robotic surgery (TORS), and
more precise intensity-modulated radiation (IMRT), there
remain many subgroups of patients (heavy-tobacco
smokers, or those with heavy nodal burden) who develop
local recurrences or distant metastases, with five-year
overall survival less than 50 % [4].
Tumor-associated angiogenesis is an established target
for therapy, with anti-angiogenic agents being actively
investigated for the treatment of multiple malignancy
types [5]. Tumor angiogenesis is a complex process
whereby endothelial cells transition from a quiescent to
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an active state in part because of cytokine signals re-
ceived from malignant cells. This process is intricately
related to tumor associated inflammation, immune eva-
sion, and metastasis [6, 7]. Several key regulators of
tumor angiogenesis have been identified, including vas-
cular endothelial growth factor (VEGF), placental growth
factor (PLGF), and angiopoietins-1 and 2 (Ang1, Ang2)
[8, 9]. VEGF also serves important immunomodulatory
roles, including inhibition of dendritic cell maturation,
expansion of regulatory T-cells (T-regs) and myeloid
derived suppressor cells (MDSCs), downregulation of ef-
fector T-cells and may also specifically impact anti-
tumor immunity [10–13]. Similar to VEGF, Ang2 can
also affect tumor immunity by augmenting the expres-
sion of immunosuppressive cytokines (i.e, IL-10) in
monocytes and macrophages, and promote the expan-
sion of T-regs [14]. Immunologic effects of Ang1 and
PLGF are less well defined in comparison to VEGF and
Ang2.
Over 90 % of HNSCC express VEGF and other angio-
genic cytokines, which serve as attractive treatment tar-
gets [15, 16]. The anti VEGF antibody, bevacizumab, has
demonstrated a survival benefit across several malignan-
cies and has also demonstrated early promising results
in head and neck cancer, producing responses in both
the primary and metastatic setting [5, 17–19]. Ang1 and
Ang2 were also overexpressed within tumor deposits in
a study of 40 patients undergoing surgical resection of
recurrent oral squamous cell carcinoma (OSCC), and
high expression of these angiogenic cytokines was corre-
lated with nodal involvement and more advanced disease
[20]. Similarly, a separate study examining 100 OSCC
tumor specimens found higher PLGF expression was as-
sociated with lymph node spread and more advanced
clinical stage [21].
Anti-angiogenic therapies can aid in sensitizing tumors
to radiation by normalizing abnormal tumor vasculature
associated with hypoxic radioresistant regions [22, 23].
Preclinical evidence in various cancers also suggests that
RT may impact tumor vasculature and perhaps anti-
tumor immunity in part by altering levels of angiogenic
cytokines in various cancers, but clinical data is limited
[24, 25]. Here, we prospectively assess changes in circu-
lating Ang-1, Ang-2, PLGF, and VEGF as a result of de-
finitive chemo-radiotherapy in HNSCC patients, and
identify tumor- and treatment-specific trends that could
aid in developing future combination regimens.
Methods
Study design and patient population
We prospectively enrolled consecutive head and neck
cancer patients receiving definitive intent head and neck
radiation with or without chemotherapy on a Dana-
Farber/Harvard Cancer Center Institutional Review
Board-approved protocol to collect longitudinal periph-
eral blood samples. In order to be eligible, all patients
needed to have gross disease above the clavicles that was
being targeted by radiation treatment and were without
evidence of metastatic disease. All patients provided in-
formed consent.
We collected baseline information from all patients in-
cluding demographics, histology, disease site, as well as
tumor and nodal stage. For squamous cell carcinomas
originating in the oropharynx or nasopharynx, we deter-
mined association with the human papilloma virus
(HPV), using both in situ hybridization for high-risk
HPV types (16 and 18), and immunohistochemistry for
the p16 protein.
All patients were prescribed a 7-week course of
curative-intent radiation with or without chemotherapy.
All patients received radiation that was graphically
planned, and with the exception of one early stage larynx
cancer patient, all patients were treated to the primary
site and bilateral neck with intensity modulated radiation
therapy (IMRT) to maximize normal tissue sparing. Ra-
diation was delivered daily Monday-Friday; all patients
were evaluated at least once weekly by the treating radi-
ation oncologist or more often if clinically warranted.
Blood samples were obtained in phlebotomy just before
the beginning and end of therapy. Blood samples were
processed within 2 h of draw. Sample processing took 30
min, and samples were stored on ice from time of col-
lecting till processing. PBMCs and plasma were stored at
–80C.
Following the completion of treatment, all patients
were followed regularly in multidisciplinary head and
neck clinic. Restaging positron emission tomography/
computed tomography (PET-CT) and CT of the head
and neck was performed approximately 3 months after
treatment or earlier if clinically indicated. Neck dissec-
tion was performed if there was suspicion for residual
disease at the three month time period. We abstracted
treatment details and information about clinical course
and potential recurrence from the medical record.
Cytokine assays
We isolated serum from blood samples using centrifuga-
tion (3000g, 10 min, 4C) and then stored these samples
at –80C. Samples that were collected were frozen imme-
diately at –80C upon centrifugation. Samples were then
thawed and aliquoted for subsequent assays, that were
then run the same day when possible. No assay was con-
ducted with 3 or more thaw cycles, and data for a par-
ticular cytokine was only compared among a uniform
number of freeze thaw cycles. We prospectively hypoth-
esized that chemoradiation would impact circulating
levels of angiogenic cytokines, and therefore serum from
a homogenous group of consecutive patients with
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squamous cell carcinoma were assayed for Ang2, VEGF,
and PLGF levels using the Bio-Plex Human Cancer Bio-
marker Panel (Biorad Laboratories Inc, Hercules, CA).
Ang1 levels were assayed using the Magnetic Luminex
Screening Assay (R&D Systems Inc, Minneapolis, MN).
All samples were tested as experimental repeats, and
measured against a standard curve of purified protein,
according to the manufacturer’s protocol [26]. Luminex
systems were quality assured via “Bio-Plex System Valid-
ation and Calibration Kits” (Bio-Rad) to test the instru-
ment prior to every assay. Moreover, the instrument is
cleaned before and after every per manufacturer proto-
col. Fluorescence intensity was measured via the Bio-
Plex MAGPIX Multiplex Reader (Biorad Laboratories
Inc, Hercules, CA).
Flow cytometry
We isolated peripheral blood mononuclear cells
(PBMCs) via centrifugation (1500 g, 20 min), and stored
the PBMCs in freezing media (10 % FBS RPMI + 10 %
DMSO) at –80C on the same day of the blood draw.
Flow cytometry was performed to quantify CD4+, CD8+
(CD3-PC7+, CD4-FITC+/CD8-APC+) and myeloid-
derived suppressor cell populations (MDSCs, CD14-
APC+, HLA-DR PC7-) via established protocols. All
antibodies were obtained from eBioscience (San Diego,
CA) except for CD8 APC (Miltenyi Biotec Inc, San
Diego, CA). FlowJo (Ashland, OR) was used for analysis.
Statistical methods
Correlations between cytokine levels and tumor and
treatment parameters including sex, age, site of primary
disease, HPV status, nodal involvement, smoking status
were evaluated using the χ2 test or pairwise Student’s t-
test. We compared changes in cytokine levels at the be-
ginning and end of therapy using non-parametric
Wilcoxon signed rank tests. Two-sided p-values < .05
were considered statistically significant and Bonferroni
corrections for multiple testing were performed where
indictated. All statistical analyses were computed using
GraphPad Prism (GraphPad Software Inc, La Jolla, CA),
or JMP Pro12 (SAS Institute Inc, Cary, NC).
Results
Patient characteristics and treatment parameters
We initially evaluated 24 consecutive patients with squa-
mous cell carcinoma whose blood samples were assessed
for angiogenic cytokines. Baseline patient characteristics
are displayed in Table 1. The median age of patients was
58 years (IQR 52.5–66). The majority of patients were
male (92 %) with locally-advanced human papilloma
virus (HPV)-associated oropharyngeal cancer. The ma-
jority of patients presented with nodal involvement, with
either one (n = 7) or two (n = 12) positive nodes. Eleven
(46 %) had smoking history of greater than 10 pack-
years. Median radiation dose delivered was 70 Gy; only
one patient received less than this dose (64 Gy). The ma-
jority of patients received concurrent chemotherapy with
Table 1 Patient characteristics
Parameter Number Percent





Base of tongue 15 63
Tonsil 4 17
Supraglottic larynx 1 4
Nasopharynx 2 8
Oral cavity 1 4




Not applicable/Unknown 2 8
Smoking
< 10 pack-years 13 54
> 10 pack-years 11 46
Concurrent chemotherapy
Bolus cisplatin 11 46
Weekly cisplatin 8 33
Carboplatin-Taxol 2 8
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radiation (n =21, 88 %). Eleven patients (52 % of patients
that received chemotherapy) received concurrent bolus
cisplatin at 100 mg/m2 every three weeks, eight (38 %)
received weekly cisplatin chemotherapy, two (10 %) re-
ceived weekly carboplatin-taxol. Median follow-up time
for all patients was 10 months (range 5–17 months);
there have been no pathologically proven local or distant
failures to date.
Circulating angiogenic cytokines
Circulating angiogenic cytokines were measured at the
beginning of treatment and then again the final week.
Comparative analysis with a control donor patient pool
at the same dilution as our cancer patients indicated that
all angiogenic cytokines were present at a higher con-
centration in head and neck cancer patients. Median
levels of VEGF, Ang1, Ang2 and PlGF at baseline were
0.46 ng/mL, 14 ng/mL, 0.33 ng/mL, and 0.16 ng/mL in
HNSCC patients, respectively, as compared to undetect-
able, 0.42 ng/mL (p < 0.0001 compared to cancer pa-
tients), undetectable/below range, and undetectable
(~0.001 ng/mL).
There were no statistically significant associations be-
tween baseline levels of VEGF, the angiopoietins, or
PLGF with sex, age at cancer diagnosis, disease subsite,
HPV-disease status, presence of nodal disease, smoking
status, or baseline red blood cell, white blood cell, plate-
let or monocyte serum levels (Additional file 1: Table
S1). Earlier T-stage was associated with increased levels
of baseline circulating VEGF (p = 0.0085, T1 compared
with higher T-stage, Fig. 1).
Changes in angiogenic cytokine levels over the course
of treatment are displayed in Fig. 2. Serum levels of
Ang1 decreased in 21/24 (88 %) patients from a median
14 ng/mL (IQR 10–16) to a median 0.6 ng/mL (IQR
0.4–1.2, p < 0.0001). Circulating levels of VEGF also
decreased in 20/24 (83 %) from a median 0.46 ng/mL
(IQR 0.31–0.66) to 0.21 ng/mL (0.14–0.26, p < 0.0001).
In contrast, serum levels of Ang2 and PLGF significantly
increased. Median Ang2 levels were 0.33 ng/mL (IQR
0.18–0.49) prior to treatment, as compared with 0.78
after (IQR 0.44–1.9, p < 0.0001), with 20/24 (83 %) pa-
tients showing increased levels. PLGF similarly increased
in 20/24 (83 %) patients from a median of 0.16 ng/mL
(IQR 0.12–0.20) at the beginning of treatment to a me-
dian of 0.26 after treatment (IQR 0.21–0.31, p < 0.0001).
All of these changes observed over the course of treat-
ment remained statistically significant after adjusting for
multiple testing.
Overall stage and disease site were not associated with
differential effects on any of the cytokines measured
(data not shown). In contrast, nodal disease was associ-
ated with degree of change in Ang2 and PLGF levels
over the course of treatment (Fig. 3). Node-negative pa-
tients demonstrate significantly less increase in Ang2
levels (median 0.057 ng/mL, IQR -0.19 to 0.28 ng/mL)
compared to node-positive patients (median 0.54 ng/mL,
IQR 0.31–1.8 ng/mL, p = 0.02). Similarly, increases in
PLGF levels were lower in node-negative patients (me-
dian 0.013 ng/mL, IQR -0.011–0.066) compared to
node-positive patients (median 0.12 ng/mL, IQR 0.088–
0.18, p = 0.008). These changes were no longer statisti-
cally significant after adjusting for multiple testing. Simi-
lar correlations were not observed with or changes in
Ang1 (p = 0.75) or changes in VEGF (p = 0.80).
In addition, we found a potential effect of concurrent
chemotherapy on changes in the levels of specific circu-
lating angiogenic cytokines (Fig. 3). Patients not under-
going concurrent chemotherapy showed significantly
smaller changes in PLGF values post-treatment (median
0.01 ng/mL, IQR 0.006–0.03) compared to patients
treated with chemotherapy (median 0.11 ng/mL, IQR
Fig. 1 Increase serum VEGF levels at baseline are inversely correlated with tumor T-stage; p-values obtained via pairwise t-tests. T1 compared with
T2 (p = 0.005), T1 compared with T3 (p = 0.03), T1 compared with T4 (p = 0.15), T2 compared with T3, T4 (p = 0.37)
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0.078–0.18, p = 0.02). The association with changes in
PLGF values was also no longer significant after adjust-
ing for multiple testing. Similarly, two out of three pa-
tients treated with radiation alone demonstrated
relatively stable levels of Ang1 and VEGF following
treatment, although with the limited number of pa-
tients treated with radiation alone the effects of
chemotherapy on changes in Ang1, Ang2, or VEGF
were not significant as compared to the overall
population studied (p = 0.36, 0.13, and 0.63, respect-
ively, Additional file 1: Table S2, Additional file 1:
Figure S1). There were there no baseline differences
in cytokine levels between the chemotherapy and no
chemotherapy groups. Additionally, the significant
changes we observed over the course of therapy for
all cytokines measured remained significant excluding
the patients who did not receive chemotherapy from
the analysis (p < 0.0001 for all cytokines).
Fig. 2 Trends in serum angiogenic cytokine concentrations comparing the beginning and end of treatment, as evaluated by non-parametric
Wilcoxon signed rank tests. Each line represents an individual patient. Serum levels of Ang1 (p < 0.0001) and VEGF decreased (p < 0.0001) over the
course of treament. In contrast, there were significant increases inserum levels of Ang2 (p < 0.0001) and PLGF (p < 0.0001)
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We also examined potential correlations between
serum cytokines and circulating CD4+, CD8+ and CD14
+/HLA-DR- MDSC cells (Additional file 1: Table S3).
There were no significant correlations between the
observed trends in cytokines and these immune
subpopulations.
To further confirm our findings and investigate the
time course of cytokine changes that we observed, an
additional 16 consecutive HNSCC patients undergoing
chemoradiation were tested over 4 time points during
therapy: the beginning (week 1), middle (week 4), end
(week 6–7) of therapy, and in follow-up (approximately
7 weeks following the completion of chemoradiation).
Evaluation of these additional patients revealed that
VEGF and Ang1 levels decreased from the beginning to
the end of treatment in 11/16 (69 %) and 15/16 (94 %),
respectively. In these patients that demonstrated a de-
crease, the middle time point demonstrated a consistent
decreasing trend in 9/11 (82 %) and 9/15 (60 %) of cases,
respectively, suggesting a constant decrease in these
angiogenic cytokines over the course of therapy. The fol-
low up time point demonstrated a more variable trend,
with further decreases in VEGF and Ang1 observed in 6/
11 (55 %), and 5/15 (33 %).
In regards to Ang2, we observed increases in 13/16
(81 %) of the additional patients, and in 8/13 (62 %) of
these the middle treatment time point supported a con-
sistent increase. In 8/13 (62 %) of these patients, the in-
crease in Ang2 continued after treatment was completed
in to the follow up time point.
Discussion
In this study, we prospectively evaluated a group of
HNSCC patients with gross disease undergoing defini-
tive radiation therapy with or without concurrent
chemotherapy. These patients had increased levels of
circulating angiogenic cytokines as compared to healthy
control donors. We measured the change in circulating
angiogenic cytokines before and after treatment and
found that levels of circulating Ang1 and VEGF
Fig. 3 Correlations between tumor, treatment parameters and circulating angiogenic cytokines, as evaluated by non-parametric Wilcoxon
signed rank tests. Changes in Ang2 (Delta-Ang2) and in PlGF (Delta-PlGF) values correlate with disease present in lymph nodes (p = 0.02,
and 0.008, respectively, top panel). Delta-PLGF values also correlate with addition of concurrent chemotherapy (p = 0.02, bottom panel)
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significantly decreased over the course of treatment
whereas Ang2 and PLGF levels increased. These changes
were significant even after adjusting for multiple testing
and were relatively consistent across demographic and
treatment variables, although the number of patients
treated with radiation alone was limited and therefore
the applicability of our results to this subgroup of pa-
tients is unproven. Interestingly, despite the fact that the
number of node negative patients was relatively small in
our study, we also found that the increases in Ang2 and
PLGF could potentially be greater in the setting of nodal
positivity.
Expression levels of angiogenic cytokines have potential
prognostic relevance across various malignancies, and can
impact response to immunotherapy. A meta-analysis of 47
studies (3476 patients) indicated that VEGF overexpres-
sion in the tumor predicts poorer overall survival and pro-
gression free survival for patients with head and neck
cancer, and also correlates with high risk of lymph node
metastases [27], however, the relationship between circu-
lating VEGF levels and outcome are not as straightforward
[28, 29]. Moreover, high levels of serum VEGF in patients
with advanced melanoma was associated with poorer
overall survival when treated with ipilimumab (anti-
CTLA4 antibody) and also predicted lack of response to
high-dose IL-2 therapy [30, 31].
PLGF and Ang2 are also implicated in pathologic angio-
genesis, and increases in these and other angiogenic cyto-
kines may help compensate when VEGF expression is
decreased or blocked [32]. Systemic upregulation of circu-
lating levels of PLGF have been observed after antiangio-
genic therapy (i.e, bevacizumab) in several malignancies,
suggesting that changes in PLGF could promote escape
from treatments that inhibit angiogenesis [33]. We extend
these findings to patients with head and neck cancer
treated with radiation, providing potential mechanistic in-
sights to the changes we observe. Elevated PLGF levels are
associated with disease progression and higher risk of
lymph node or distant metastases in colorectal, gastric,
breast, lung, thyroid cancers, and oral SCC [34, 35]. In
vitro models of oral squamous cell and larynx carcinoma
have shown that PLGF increases expression of matrix me-
talloproteinases that promote pathologic neovasculariza-
tion, and that PLGF inhibition slows this process [36, 37].
Similar to VEGF, PLGF may also inhibit dendritic cell
maturation by signaling through VEGFR1 [38]. Serum
levels of Ang2 were elevated at baseline in 143 breast can-
cer patients compared to 100 healthy controls, and the 5-
year overall survival was significantly lower in the Ang2
high expression group compared to patients with low
serum Ang2 [39]. With respect to HNSCC cancers, Ang2
expression was increased in 85 oral SCC patients com-
pared to 37 controls, and was associated with worse sur-
vival at 5-year follow up [40]. Ang2 also has important
effects on Tie2 expressing monocytes that may affect anti-
tumor immunity [41], with some long-term responders to
GM-CSF based cellular vaccines delivered with or without
CTLA-4 blockade developing functional Ang-2 blocking
antibodies over time [42]. Antibodies to multiple angio-
genic cytokines including Ang2 were also found to be as-
sociated with improved survival following hematopoetic
stem cell transplantation and GM-CSF based vaccine ad-
ministered to treat leukemia [43].
Previous studies have indicated that chemoradiation
therapy has complex effects on the tumor microenviron-
ment that may significantly impact angiogenesis and
anti-tumor immunity. Forty-six patients with esophageal
cancer treated with concurrent chemoradiation to 60–64
Gy showed significant decreases in serum VEGF levels,
with the changes correlating with overall survival at
two-year follow up [44]. Twenty non-Hodgkin’s lymph-
oma patients treated to median 26 Gy also showed
serum VEGF levels decline post-RT, as did 37 patients
with pharyngeal and laryngeal SCC treated to a total
dose of 40 Gy [24, 45]. Prior animal studies have exam-
ined the importance of VEGF in tumor associated angio-
genesis and tumor growth, and the expression of this
cytokine by head and neck squamous cell carcinoma
lines driven by MEK-MAPK and IKK-NF-Kb pathways
[46]. Studies on the effects of radiation on Ang1 or
Ang2 are much more limited, but a preclinical model
treated to 10 Gy whole-brain irradiation led to signifi-
cant decreases in VEGF, Ang-1 and Tie-2 tissue expres-
sion but increased Ang-2 expression [47]. This was
intimately associated with the inhibition of endothelial
cell proliferation and increased levels of endothelial cell
apoptosis, and blocking Ang2 in this setting has led to
benefit in preclinical models [48, 49]. The functional role
of increased levels of PLGF is controversial, with some
suggestion that systemic upregulation may promote re-
sistance to anti-VEGF therapy as mentioned above, and
others suggesting that increased PLGF may actually
functionally impair angiogenesis and predict response to
antiangiogenic therapy [50]. Our results were consistent
with the prior studies that demonstrate that radiation is
associated with decreases in VEGF and Ang1, and an in-
crease in Ang2; these findings are potentially consistent
with endothelial cell apoptosis as well as complex effects
on angiogenesis and anti tumor immunity that need to
be further explored in preclinical models that can better
elucidate the functional consequences of the effects that
we have observed.
There are several potential mechanisms that explain
the observed trends in circulating angiogenic cyto-
kines. Decreases in VEGF may parallel tumor re-
sponse or decreases in tumor associated macrophages.
Tumor debulking caused by chemoradiation could
also contribute to VEGFR1 shedding from tumors,
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that could then bind VEGF and result in decreased
VEGF detected in serum. However, free VEGF may be
the more biologically active form. Chemoradiation in-
duced endothelial cell apoptosis can cause increases
in Ang2 and decreases in Ang1 as the vasculature re-
models. Tissue injury has been shown to directly in-
crease Ang2 mRNA expression in mouse models [51].
Increases in PLGF could also be the result of com-
pensatory secretion from stressed fibroblasts within
the radiation field, as has been previously suggested
[52, 53], and the relationship between Ang2, PLGF in-
creases and lymph node involvement might be due to
patients with nodal disease receiving radiation to lar-
ger fields. Angiogenic cytokines also interact with one
another, and the combination of parallel trends across
multiple cytokines presented here is likely more in-
formative than examining individual cytokines in iso-
lation. For example, PLGF can form heterodimers
with VEGF and limit VEGF:VEGF homodimerization.
In some cases, increased PLGF has been shown to be
a positive marker with Ang2 for vessel normalization
inhibiting tumor metastasis. Future mechanistic stud-
ies are needed to elucidate the exact mechanism
underlying the trends observed.
There are limitations to our study. We prospectively in-
cluded twenty-four consecutive patients from a single insti-
tution and then tested an additional 16 patients across 4
time points. However, analyses in larger cohorts, ideally
with more time points evaluated would be helpful to fur-
ther validate our findings and allow for more subgroup ana-
lyses and provide additional insights as to the biology
underlying the changes we observed. Although we
attempted to limit variability in processing of samples and
specifically freeze-thaw cycles, we cannot exclude this as a
potential confounder. We selected a relatively homogenous
group of patients for this analysis; therefore we are unable
to discern dose-dependent effects or impacts across a di-
verse range of histologies. The majority of patients were
treated with chemoradiation; therefore, impacts in patients
treated with radiation alone should be explored in more de-
tail. However, the similar underlying pathologies and uni-
form treatment protocols does allow us greater confidence
in interpreting the trends observed between individual pa-
tients. Node negative and radiotherapy only subgroups are
relatively small, and therefore, associations with these fac-
tors should be interpreted with caution. None of our pa-
tients were treated with anti-angiogenic therapies (i.e.,
bevacizumab), so it not possible for us to determine syner-
gies that may exist with combination treatments. Finally,
because we enrolled a disease population with very good
prognosis our purpose was not to draw conclusions about
associations between angiogenic cytokine levels and
disease-specific outcomes. Instead, our results may provide
insight into systemic effects of focused chemoradiation that
may impact response to other therapies target the tumor
vasculature or systemic antitumor immunity.
Anti-VEGF therapies (bevacizumab) have been ex-
plored in head and neck cancer and in combination with
immunotherapy. A phase I trial of 10 locoregionally ad-
vanced HNSCC patients combining bevacizumab with
concurrent chemoradiation (70 Gy, weekly cisplatin) re-
ported a complete response in all patients, with a mean
survival time of 61 months [5]. A phase II trial of 46 pa-
tients with recurrent or metastatic HNSCC receiving
bevacizumab and cetuximab reported an overall re-
sponse rate of 16 % and median overall survival of 7.5
months [18]. Their analyses of baseline and post-
treatment serum samples from 20 patients indicated a
decrease in VEGF and an increase in PLGF post-
treatment, which is similar to the effects we have
observed.
Conclusion
Our study suggests that localized head and neck che-
moradiation significantly impacts circulating angio-
genic cytokines, increasing decreasing VEGF and
Ang1 and increasing Ang2 and PLGF. These changes
may provide insights as to the biology of HNSCC and
compensatory angiogenic pathways potentially acti-
vated when circulating VEGF levels are decreased,
and also suggest a potential mechanism by which fo-
cused chemoradiation may impact systemic immunity
and T-cell infiltration at distant sites. Ongoing and
planned studies continue to examine the role of
VEGF inhibition in HNSCC (NCT00588770,
NCT01639911), as well as study combining immuno-
therapy with anti-angiogenic therapy (NCT02210117,
NCT02348008, NCT02141542). The results of our
study provide additional rationale to support targeting
additional angiogenic cytokines such as Ang2 and
PLGF, especially when combined with chemoradiation,
and potentially continuing these therapies in the adju-
vant setting given the continued rise in Ang2 that we
observed in the majority of patients. Finally, our study
also provides additional rationale for testing targeted
radiation in combination with immunotherapy to pro-
mote antitumor immune responses.
Additional file
Additional file 1: Table S1. Associations between angiogenic
cytokine levels at baseline and clinical parameters (Wilcoxon Rank
Sum p-values for discrete; ANOVA p-values for continuous variables).
Table S2. Angiogenic cytokine levels in patients treated with
radiation without concurrent chemotherapy (pg/mL). Table S3.
Correlation between angiogenic cyokines and immune cell populations
(ANOVA significance values). Figure S1. Changes in cytokine levels in
patients treated with radiation without concurrent chemotherapy.
(DOCX 183 kb)
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